Kevin Kalinsky, MD
Updated data with CDK4/6 and PI3K inhibitors showing progression-free and overall survival (OS) benefits are transforming the hormone receptor (HR)–positive, HER2-negative breast cancer arena, according to Kevin Kalinsky, MD, MS.
“HR-positive, HER2-negative breast cancer is the most common type of breast cancer that we see, and we have a landscape in which we are adding in targeted drugs, CDK4/6 inhibitors, and an mTOR inhibitor,” said Kalinsky, an assistant professor of medicine, Department of Medicine, at Herbert Irving Comprehensive Cancer Center, NewYork-Presbyterian Hospital/Columbia University Medical Center.
The 3 FDA-approved CDK4/6 inhibitors—palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenio)—have continued to demonstrate efficacy and improvements in progression-free survival (PFS) in select patients with HR-positive, HER2-negative disease. Most recently, results from the PALOMA-3 trial showed that the combination of palbociclib plus fulvestrant (Faslodex) led to a clinically meaningful benefit in OS in some patients with advanced breast cancer who had progressed or relapsed on prior endocrine therapy.1
The regimen showed a 10.0-month OS improvement in patients who were sensitive to previous endocrine therapy.
... to read the full story